

## CORRECTION

Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT, for the E-Five Investigators Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice: 12-Month Data From the E-Five Registry. *J Am Coll Cardiol Intv* 2009;2:1227–35.

In Table 3, the n reported in the standard-use column heading should be 2,008, not 2,125; and the n reported in the extended-use column heading should be 5,824, not 6,189. The corrected table is printed below. The authors regret this error.

doi:10.1016/j.jcin.2010.01.009

<b>Table 3. 12-Month Clinical Outcomes for Overall Population and Patients With Standard Versus Extended-Use Clinical and Lesion Characteristics</b>				
	<b>Overall (n = 7,832)</b>	<b>Standard-Use (n = 2,008)</b>	<b>Extended-Use (n = 5,824)</b>	<b>p Value (Standard vs. Extended-Use)</b>
Death (all)	2.4 (191)	1.2 (24)	2.9 (167)	<0.001
Cardiac	1.7 (135)	0.9 (19)	2.0 (116)	<0.001
MI (all)	1.6 (128)	0.7 (15)	1.9 (113)	<0.001
Q-wave	0.4 (31)	0.2 (4)	0.5 (27)	0.147
Non-Q-wave	1.3 (98)	0.5 (11)	1.5 (87)	0.001
Death (cardiac) + MI (all)	3.0 (238)	1.5 (30)	1.6 (208)	0.001
ARC definite stent thrombosis	0.6 (49)	0.1 (3)	0.8 (46)	<0.001
0–30 days	0.4 (28)	0.1 (2)	0.4 (26)	0.028
31–365 days	0.3 (23)	0.0 (1)	0.4 (22)	0.015
ARC definite + probable stent thrombosis	1.1 (88)	0.4 (9)	1.4 (79)	<0.001
0–30 days	0.8 (59)	0.4 (8)	0.9 (51)	0.035
31–365 days	0.4 (31)	0.0 (1)	0.5 (30)	0.002
All ARC stent thrombosis	1.8 (144)	0.8 (16)	2.2 (128)	<0.001
0–30 days	0.8 (59)	0.4 (8)	0.9 (51)	0.035
31–365 days	1.1 (89)	0.4 (9)	1.4 (80)	<0.001
Per protocol stent thrombosis	1.0 (82)	0.4 (9)	1.3 (73)	0.001
0–30 days	0.8 (62)	0.4 (8)	0.9 (54)	0.019
31–365 days	0.3 (21)	0.0 (1)	0.3 (20)	0.024
TLR	4.5 (349)	2.8 (56)	5.0 (293)	<0.001
TVR	4.9 (387)	3.0 (61)	5.6 (326)	<0.001
TVR (nontarget lesion)	0.7 (52)	0.3 (6)	0.8 (46)	0.017
TVF	7.2 (565)	4.3 (87)	8.2 (478)	<0.001
MACE	7.5 (587)	4.3 (87)	8.6 (500)	<0.001

Values are % (n).  
 ARC = Academic Research Consortium; MACE = major adverse cardiac events; MI = myocardial infarction; TLR = target lesion revascularization; TVF = target vessel failure; TVR = target vessel revascularization.